Concepedia

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

Eric Nuermberger, Sandeep Tyagi, Rokeya Tasneen, Kathy N. Williams, Deepak V. Almeida, Ian M. Rosenthal, J Grosset

Antimicrobial Agents and Chemotherapy · 2008 · 198 citations · 7 references

DOIFull text

Open access

Concepts

Abstract

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

References

7

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

C. Kendall Stover, Paul Warrener, Donald R. VanDevanter et al. · Nature · 2000 · 1K citations

, , +7

OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice

Makoto Matsumoto, Hiroyuki Hashizume, Tatsuo Tomishige et al. · PLoS Medicine · 2006 · 740 citations · Full text

, , +13

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

Eric L. Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 317 citations

, , +14

The Need for New Drugs against Tuberculosis

Richard O’Brien, Paul Nunn · American Journal of Respiratory and Critical Care Medicine · 2001 · 222 citations

, , +12

Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis

Eric Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi et al. · American Journal of Respiratory and Critical Care Medicine · 2004 · 221 citations

, , +12